文献速递泌尿生殖骨肌技术与安全PETCT

以前列腺穿刺活检验证的PSMA-PET/CT诊断前列腺癌骨转移的表现

Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.
PubMed 文献 · Skeletal Radiol · 2024-12-20

本研究为单中心回顾性研究,纳入80例前列腺癌患者,对PSMA-PET/CT上示踪剂浓聚的骨病灶行CT引导下骨活检,评估PSMA-PET/CT与组织病理学的一致性和阳性预测值。结果显示两者一致率为69%(55/80),阳性预测值为66%(53/80);脊柱、骨盆和肋骨活检的阳性预测值分别为82%、72%和26%;峰值SUV与肝脏平均SUV比值阈值为1.7时,敏感度61%、特异度92%。

要点

  • PSMA-PET/CT与骨活检组织病理学的一致率为69%(55/80),阳性预测值为66%(53/80)。
  • 肋骨病灶活检阳性预测值仅26%(5/19),多数活检的肋骨病灶为转移阴性。
  • 峰值SUV与肝脏平均SUV比值阈值为1.7时,敏感度61%、特异度92%。

核心结论

  • PSMA-PET/CT对前列腺癌骨转移的诊断具有中等偏高的组织病理学一致性和阳性预测值;峰值SUV有助于区分活检阳性与阴性病灶;与既往研究一致,多数活检的肋骨病灶为转移阴性。

研究设计与样本

  • 单中心回顾性研究,纳入80例前列腺癌患者,采用18F-piflufolastat行PSMA-PET/CT,对示踪剂浓聚的骨病灶行CT引导下骨活检作为组织病理学金标准。

关键影像表现/征象

  • PSMA-PET/CT与骨活检结果一致的患者为55/80(69%)。
  • 脊柱、骨盆和肋骨活检的阳性预测值分别为82%(23/28)、72%(18/25)和26%(5/19)。
  • 活检阳性病灶的峰值SUV及其与肝脏平均SUV的比值均显著高于活检阴性病灶。

诊断标准与关键数值

  • PSMA-PET/CT对前列腺癌骨转移的阳性预测值为66%(53/80)。
  • 峰值SUV与肝脏平均SUV比值阈值为1.7时,对转移性前列腺癌组织病理学诊断的敏感度为61%、特异度为92%。

临床应用与阅片要点

  • 阅片时需注意肋骨病灶的阳性预测值较低(26%),活检证实的肋骨病灶多数为转移阴性。
  • 峰值SUV及其与肝脏平均SUV的比值有助于区分活检阳性与活检阴性骨病灶。

局限性

  • 本研究为单中心回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Prostate-specific membrane antigen (PSMA)-PET/CT has shown considerable promise in the evaluation of prostate cancer bone metastases; however, data utilizing a histopathologic reference standard in this setting are limited. We therefore sought to evaluate the diagnostic performance of PSMA-PET/CT using a consistent histopathologic gold standard in the form of bone biopsy.

MATERIALS AND METHODS: In this single-center, retrospective study, we identified 80 patients with prostate cancer who underwent CT-guided bone biopsy of a tracer-avid osseous lesion on PSMA-PET/CT performed with 18F-piflufolastat. Concordance between PET/CT and histopathology and the positive predictive value of PSMA-PET/CT were determined. Factors predictive of positive biopsies were also evaluated.

RESULTS: PSMA-PET/CT and bone biopsy results were concordant in 55/80 patients (69%), and the positive predictive value of PSMA-PET/CT for osseous metastasis of prostate cancer was 66% (53/80). Positive predictive values for spine, pelvis, and rib biopsies were 82% (23/28), 72% (18/25), and 26% (5/19), respectively. Peak SUV and its ratio to liver mean SUV were significantly higher in biopsy-positive lesions compared to biopsy-negative lesions. A threshold peak SUV to liver mean SUV ratio of 1.7 had a sensitivity of 61% and a specificity of 92% for a histopathologic diagnosis of metastatic prostate cancer.

CONCLUSION: PSMA-PET/CT has a moderately high histopathologic concordance and positive predictive value for the diagnosis of osseous metastatic disease in prostate cancer. Peak SUV is useful for distinguishing biopsy-positive from biopsy-negative lesions. In keeping with prior investigations, a majority of biopsied rib lesions were negative for metastatic prostate cancer.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Ou WC, Jennings JW, Northrup BE, et al. Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer. Skeletal Radiol. 2024. PMID: 39704796. doi:10.1007/s00256-024-04855-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。